Credit: Image source: Getty Images.What happened
Shares of Progenics Pharmaceuticals (NASDAQ: PGNX) are down 10.5% at 12:53 p.m. EDT Friday after announcing after the bell yesterday that the Food and Drug Administration will take an additional three months to review the marketing application for Azedra, a treatment for malignant, recurrent, and/or unresectable pheochromocytoma and paraganglioma, which are rare types of neuroendocrine tumors.
So what
Investors had been piling into Progenics' stock ahead of an FDA decision that was expected on or before the Prescription Drug User Fee Act (PDUFA) action date of April 30. But the guidelines laid out in PDUFA allow the FDA to extend its goal date by three months when a company submits extensive additional data during the review.
In this case, Progenics noted that the data was for the chemistry, manufacturing, and controls section of the marketing application and isn't related to the safety of efficacy of Azedra. While that should give investors some confidence in an eventual approval, Progenics didn't give any further details, making it hard to know the extent of the FDA's questions and whether Progenics has satisfied the agency.
Image source: Getty Images.
Now what
If Azedra ends up getting approved, a three month delay isn't worthy of a 10% decline in the stock price, especially since the delay could actually be shorter because the PDUFA date is just a goal the agency is trying to meet.
Investors are likely selling today because they're worried that the delay is a sign of a bigger issue that Progenics can't fix easily, although arguably a huge problem would have just resulted in an FDA rejection rather than the agency allowing the company to submit additional data to answer its questions. The other possibility is the stock is down as impatient traders who were looking to hold over the binary event are selling their shares and moving on.
Long-term investors willing to assume the extra unknown risk associated with potential manufacturing problems can pick up shares of Progenics on sale today, but without more information, it's hard to know exactly how risky a venture that is.
10 stocks we like better than Progenics Pharmaceuticals
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Progenics Pharmaceuticals wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of March 5, 2018
Brian Orelli and The Motley Fool have no position in any of the stocks mentioned. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
